SCHEMBL838095

SCHEMBL838095

COc1ccc(Nc2cc(C)c3ccccc3n2)cc1C

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.71
MEN1 O00255 5/20 0.71
KMT2A Q03164 5/20 0.71
KDM4E B2RXH2 4/20 0.71
RAB9A P51151 2/20 0.71
SMN1; SMN2 Q16637 2/20 0.71
LMNA P02545 1/20 0.71
POLB P06746 2/20 0.68
NPC1 O15118 1/20 0.65
ABCB1 P08183 3/20 0.49
ABCC1 P33527 3/20 0.49
ABCG2 Q9UNQ0 3/20 0.49
GAA P10253 1/20 0.48
GFER P55789 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
LRRK2 Q5S007 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10110706 0.88 MAPT (0.67) MAPTMEN1KMT2AKDM4ERAB9A
SCHEMBL837757 0.88 MAPT (0.67) MAPTMEN1KMT2AKDM4ERAB9A
SCHEMBL837692 0.81 MEN1 (0.75) MAPTMEN1KMT2AKDM4ERAB9A
SCHEMBL838120 0.80 MEN1 (0.79) MAPTMEN1KMT2AKDM4ERAB9A
SCHEMBL837706 0.80 MEN1 (0.74) MAPTMEN1KMT2AKDM4ERAB9A
SCHEMBL838429 0.77 KMT2A (0.70) MAPTMEN1KMT2AKDM4ERAB9A
SCHEMBL30917200 0.77 KMT2A (0.70) MAPTMEN1KMT2AKDM4ERAB9A
SCHEMBL4817753 0.77 KDM4E (0.70) MAPTMEN1KMT2AKDM4ERAB9A
SCHEMBL16621247 0.76 MEN1 (0.51) MAPTMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL13126873 0.75 SYK (0.56) MAPTKMT2ARAB9ALMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143295-B2 Compounds having activity in correcting mutant-CFTR processing and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-03-27 US disclosed
US-20080318984-A1 Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318984-A1 Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof CFTR, ABCC5, QPCT MAPT 4358/4885MEN1 4634/4885KMT2A 4258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.